By integrating anti-aging research with AD prevention, this study aims to explore Rapamycin as a potential strategy to mitigate AD risk in high-risk APOE4 populations while uncovering genotype-specific responses to treatment. This evidence concerns the gene APOE and Alzheimer disease.